Blog
RSS FeedPosted by Michael Wonder on 30 Jan 2024
2024 PBS post-market review framework
31 January 2024 - The 2024 post-market review framework is now available. ...
Posted by Michael Wonder on 23 Sep 2019
NICE seeks feedback from users of the evidence standards framework for digital health technologies
23 September 2019 - Consultation on priority areas open to stakeholders until mid October. ...
Posted by Michael Wonder on 18 Sep 2019
Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications
16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...
Posted by Michael Wonder on 18 Apr 2018
The use of MCDA in HTA: great potential, but more effort needed
18 April 2018 - The potential for multi-criteria decision analysis (MCDA) to support health technology assessment (HTA) has been much discussed, ...
Posted by Michael Wonder on 13 Apr 2018
Decision components of NICE's technology appraisals assessment framework
10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 28 Aug 2017
How to design the cost-effectiveness appraisal process of new health care technologies to maximise population health: a conceptual framework
22 August 2017 - This paper presents a conceptual framework to analyse the design of the cost-effectiveness appraisal process of new ...
Posted by Michael Wonder on 24 Aug 2017
Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet?
23 August 2017 - There is emerging interest in the use of discrete choice experiments as a means of quantifying the ...
Posted by Michael Wonder on 02 Feb 2017
Quality over quantity more important in health outcomes
2 February 2017 - When it comes to making a difference in people’s lives, it’s not about how many medicines ...
Posted by Michael Wonder on 11 Oct 2016
Cost, effectiveness, and value. How to judge?
11 October 2016 - Former NICE Chairman Sir Michael Rawlins offers his views in JAMA. ...
Posted by Michael Wonder on 05 Jul 2016
New Zealand public help improve PHARMAC decision making
6 July 2016 - After listening to what New Zealanders had to say, PHARMAC has changed the way it makes decisions ...
Posted by Michael Wonder on 05 Jul 2016
Factors for consideration
30 June 2016 - The factors for consideration are the framework PHARMAC uses when making funding decisions. ...